Literature DB >> 28984732

The clinical performance of dabigatran in the Italian real-life experience.

Vincenzo Russo1, Anna Rago, Antonio D'Onofrio, Gerardo Nigro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28984732     DOI： 10.2459/JCM.0000000000000548

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN： 1558-2027            Impact factor:   2.160


× No keyword cloud information.
  9 in total

1.  Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study.

Authors:  Vincenzo Russo; Anna Rago; Andrea Antonio Papa; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

2.  Complete resolution of left atrial appendage thrombosis with oral dabigatran etexilate in a patient with Myotonic Dystrophy type 1 and atrial fibrillation.

Authors:  Anna Rago; Andrea Antonio Papa; Giulia Arena; Marco Mosella; Antonio Cassese; Alberto Palladino; Paolo Golino
Journal:  Acta Myol       Date:  2017-12-01

3.  Myotonic dystrophy type 1 and pulmonary embolism: successful thrombus resolution with dabigatran etexilate therapy.

Authors:  Emanuele Gallinoro; Andrea Antonio Papa; Anna Rago; Simona Sperlongano; Antonio Cassese; Nadia Della Cioppa; Maria Cristina Giada Magliocca; Giovanni Cimmino; Paolo Golino
Journal:  Acta Myol       Date:  2018-09-01

4.  Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study.

Authors:  Vincenzo Russo; Anna Rago; Riccardo Proietti; Emilio Attena; Carmen Rainone; Mario Crisci; Andrea Antonio Papa; Paolo Calabrò; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro
Journal:  Biomed Res Int       Date:  2019-02-13       Impact factor: 3.411

Review 5.  Diagnosis and Management of Left Atrium Appendage Thrombosis in Atrial Fibrillation Patients Undergoing Cardioversion.

Authors:  Enrico Melillo; Giuseppe Palmiero; Adele Ferro; Paola Elvira Mocavero; Vittorio Monda; Luigi Ascione
Journal:  Medicina (Kaunas)       Date:  2019-08-21       Impact factor: 2.430

Review 6.  Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.

Authors:  Alfredo Caturano; Raffaele Galiero; Pia Clara Pafundi
Journal:  Medicina (Kaunas)       Date:  2019-09-20       Impact factor: 2.430

Review 7.  Cognitive Function and Atrial Fibrillation: From the Strength of Relationship to the Dark Side of Prevention. Is There a Contribution from Sinus Rhythm Restoration and Maintenance?

Authors:  Emanuele Gallinoro; Saverio D'Elia; Dario Prozzo; Michele Lioncino; Francesco Natale; Paolo Golino; Giovanni Cimmino
Journal:  Medicina (Kaunas)       Date:  2019-09-13       Impact factor: 2.430

8.  Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study.

Authors:  Anna Rago; Enrica Pezzullo; Marco Malvezzi Caracciolo d'Aquino; Gabriella Scognamiglio; Valentina Maria Caso; Francesco Martone; Emilio Attena; Valentina Parisi; Antonio D'Onofrio; Paolo Golino; Gerardo Nigro; Vincenzo Russo
Journal:  J Blood Med       Date:  2021-06-04

9.  Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study.

Authors:  Anna Rago; Andrea Antonio Papa; Emilio Attena; Valentina Parisi; Paolo Golino; Gerardo Nigro; Vincenzo Russo
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-18       Impact factor: 3.727
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.